Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Nurix Therapeutics, Inc. (NRIX) had Return on Tangible Equity of -18.13% for the most recently reported fiscal quarter, ending 2026-02-28.
| Income Statement Financials | |
$6.25M |
|
$-87.17M |
|
-- |
|
$6.25M |
|
$98.75M |
|
$-92.50M |
|
$5.32M |
|
$-87.17M |
|
$-87.17M |
|
$-87.17M |
|
$-87.17M |
|
$-87.17M |
|
$-87.17M |
|
$-92.50M |
|
$-88.72M |
|
110.07M |
|
110.07M |
|
$-0.79 |
|
$-0.79 |
|
| Balance Sheet Financials | |
$554.39M |
|
$21.70M |
|
$81.74M |
|
$636.13M |
|
$92.20M |
|
-- |
|
$63.04M |
|
$155.24M |
|
$480.89M |
|
$480.89M |
|
$480.89M |
|
103.40M |
|
| Cash Flow Statement Financials | |
$-71.91M |
|
$-123.83M |
|
$19.98M |
|
$247.93M |
|
$72.16M |
|
$-175.76M |
|
$9.40M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
6.01 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-1479.45% |
|
-1479.45% |
|
-- |
|
-1394.34% |
|
-1394.34% |
|
$-72.96M |
|
-- |
|
-- |
|
-- |
|
0.01 |
|
-- |
|
-- |
|
-- |
|
-18.13% |
|
|
Return on Tangible Equity |
-18.13% |
-13.70% |
|
-18.13% |
|
$4.65 |
|
$-0.66 |
|
$-0.65 |
|